Trial
NCT01953601
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Amnestic Mild Cognitive Impairment
Intervention
Verubecestat 12 mg (Parts 1 and 2)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-17